bs-34036R

[Primary Antibody]

CD130 Rabbit pAb



www.bioss.com.cn sales@bioss.com.cn techsupport@bioss.com.cn 400-901-9800

- DATASHEET		400-901-9800
Host: Rabbit	Isotype: IgG	Applications: WB (1:500-2000)
Clonality: Polyclonal	-	IHC-P (1:100-500)
GenelD: 3572	SWISS: P40189	IF (1:50-100)
Target: CD130		ELISA (1:5000-10000)
Immunogen: Recombinant human CD130 protein: 675-860.		Reactivity: Human, Mouse, Rat
Purification: affinity purified by	Protein A	
Concentration: 1mg/ml		
 Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. Background: bs-1459P is one synthetic peptide derived from human IL6R beta. CD130 is a signal transducer shared by many cytokines, including interleukin 6 (IL6), ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), and oncostatin M (OSM). This protein functions as a part of the cytokine receptor complex. The activation of this protein is dependent upon the binding of cytokines to their receptors. vIL6, a protein related to IL6 and encoded by the Kaposi sarcoma-associated herpesvirus, can bypass the interleukin 6 receptor (IL6R) and directly activate this protein. Knockout studies in mice suggested a critical role of the gene encoding this protein in regulating myocyte apoptosis. Alternatively spliced transcript variants encoding distinct isoforms have been described. 		Predicted MW.: ^{103 kDa} Subcellular Location: Secreted ,Cell membrane

— VALIDATION IMAGES



Sample: Lane 1: Heart (Mouse) Lysate at 40 ug Lane 2: Liver (Rat) Lysate at 40 ug Lane 3: HepG2 (Human) Cell Lysate at 30 ug Lane 4: Hela (Human) Cell Lysate at 30 ug Lane 5: Huvec (Human) Cell Lysate at 30 ug Lane 6: A549 (Human) Cell Lysate at 30 ug Lane 7: U87MG (Human) Cell Lysate at 30 ug Primary: Anti-CD130 (bs-34036R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 130 kD Observed band size: 140 kD

- SELECTED CITATIONS -----

• [IF=1.4] Kun Zhao. et al.IL6ST: A Novel Therapeutic Target for Managing and Treating Colorectal Cancer Via Ferroptosis.turk j gastroenterol.2024 Jun 6;35(9):690-698. IHC ;Human. 39344518